Want to see BCAX full AI Analyst Report?
Top Page
Bicara Therapeutics Inc.
(NASDAQ:BCAX)
Select Model
Select Model
Rating:64Neutral
Price Target:
$30.00
▲(11.03% Upside)
Action:Reiterated
Date:08/11/26
BCAX scores in the mid-range primarily because strong earnings-call momentum (clinical progress, clear milestones, and multi-year cash runway) and constructive technical trends offset weak underlying financial performance typical of a pre-revenue biotech (widening losses and significant cash burn). Valuation is a modest drag due to a negative P/E and no dividend yield.
Positive Factors
Durable 3-year efficacy signal
Three-year survival data showing roughly one in three patients alive at three years at the pivotal dose represent a durable clinical benefit signal. That level of differentiated efficacy materially de-risks Phase III readouts, strengthens future label/market positioning, and supports long-term uptake by clinicians and payers if confirmed.
Negative Factors
Pre‑revenue with widening losses
The company remains pre-revenue with materially widening net losses over recent years. Persistent negative earnings means long-term value creation depends entirely on clinical and regulatory success; failure or delays could force dilutive financings and impair shareholder returns over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Durable 3-year efficacy signal
Three-year survival data showing roughly one in three patients alive at three years at the pivotal dose represent a durable clinical benefit signal. That level of differentiated efficacy materially de-risks Phase III readouts, strengthens future label/market positioning, and supports long-term uptake by clinicians and payers if confirmed.
Read all positive factors
Bicara Therapeutics Inc. (BCAX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.61B
Dividend YieldN/A
Average Volume (3M)829.98K
Price to Earnings (P/E)―
Beta (1Y)1.44
Revenue GrowthN/A
EPS Growth-63.70%
CountryUS
Employees103
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.10
Shares Outstanding66,172,935
10 Day Avg. Volume408,617
30 Day Avg. Volume829,976
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)2.29
Price to Sales (P/S)0.00
P/FCF Ratio-8.59
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$33.18Price Target Upside22.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.47
Revenue Forecast (FY)N/A
Bicara Therapeutics Inc. Business Overview & Revenue Model
Company Description
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tum...
How the Company Makes Money
null...
Bicara Therapeutics Inc. Earnings Call Summary
Earnings Call Date:Aug 11, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 17, 2026
Earnings Call Sentiment Positive
The call conveyed strong clinical and operational momentum: mature 3-year efficacy and safety data for Ficera (≈33% 3-year survival, ~2x SOC), clear milestones (interim OS analysis mid-2027), initiation of an alternative dosing study timed for potential approval, and a planned leadership succession to support commercialization. These positives are balanced against rising operating expenses and planned commercialization spend, competitive timing uncertainty from other EGFR-directed agents, and small early CRC cohorts that will require further validation. Overall, the highlights—particularly the robust long-term efficacy signal, funded runway into H1 2029, and deliberate commercialization preparations—outweigh the near-term execution and competitive risks.Positive Updates
Pivotal Phase III (FORTIFI-HN01) Progress
FORTIFI-HN01 is on track for substantial enrollment by year-end with over 200 sites now active and sustained investigator engagement; company positioned for a top-line interim overall survival analysis in mid-2027.
Negative Updates
Rising Operating Expenses
Total operating expenses for Q2 2026 increased versus Q2 2025 driven by clinical operations, development and manufacturing costs and higher personnel-related expenses (including stock-based compensation); management expects quarter-over-quarter operating expenses to increase for the remainder of the year.
Read all updates
Q2-2026 Updates
Positive
Negative
Pivotal Phase III (FORTIFI-HN01) Progress
FORTIFI-HN01 is on track for substantial enrollment by year-end with over 200 sites now active and sustained investigator engagement; company positioned for a top-line interim overall survival analysis in mid-2027.
Read all positive updates
Company Guidance
Management guided that Bicara expects to be substantially enrolled in the pivotal Phase III FORTIFI‑HN01 by year‑end 2026 (>200 active sites, ~20% U.S. sites; pivotal dose 1,500 mg weekly), positioning the company for a top‑line interim analysis in mid‑2027; they have initiated the FORTIFI‑FLEX alternative dosing study (≈1/3 site overlap with FORTIFI) to support a loading + every‑3‑week maintenance regimen with data aimed to be in hand by potential U.S. approval. Financially, Bicara ended Q2 2026 with ≈$497M in cash, cash equivalents and marketable securities, which management said provides runway into H1 2029 to fund the pivotal OS analysis, a planned regulatory filing, initial commercial/medical investments, FORTIFI‑FLEX and manufacturing; they also cautioned that operating expenses have increased year‑over‑year and are expected to rise quarter‑over‑quarter through year‑end as clinical, technical and commercial readiness investments continue. They reiterated clinical progress from Phase Ib (~90 patients across 3 dose cohorts, up to 3 years follow‑up), noting at the 1,500 mg weekly dose an estimated ~1 in 3 patients alive at 3 years (~33%, nearly 2× OS versus retrospective pembrolizumab).Bicara Therapeutics Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -184.38M | -137.63M | -67.75M | -51.96M | -37.72M |
| Net Income | -185.36M | -137.95M | -68.00M | -51.98M | -37.84M |
Balance Sheet | |||||
| Total Assets | 512.24M | 430.99M | 569.20M | 233.98M | 6.70M |
| Cash, Cash Equivalents and Short-Term Investments | 497.26M | 414.80M | 489.71M | 230.44M | 4.16M |
| Total Debt | 1.16M | 1.71M | 738.00K | 657.00K | 0.00 |
| Total Liabilities | 43.48M | 29.54M | 77.32M | 15.47M | 23.98M |
| Stockholders Equity | 468.77M | 401.45M | 491.88M | 218.51M | -17.28M |
Cash Flow | |||||
| Free Cash Flow | -135.25M | -107.11M | -74.82M | -46.21M | -32.27M |
| Operating Cash Flow | -134.85M | -106.83M | -74.75M | -45.63M | -32.08M |
| Investing Cash Flow | -402.50M | -318.45M | -9.00K | -586.00K | -192.00K |
| Financing Cash Flow | 197.34M | 32.26M | 334.03M | 272.50M | 31.70M |
Bicara Therapeutics Inc. Risk Analysis
Bicara Therapeutics Inc. disclosed 83 risk factors in its most recent earnings report. Bicara Therapeutics Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
our existing business, could have a material adverse effect on our operating results, dilute our stockholders' ownership, increase our debt or cause us to incur significant expense. Q1, 2026
Bicara Therapeutics Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $1.61B | -7.83 | -41.49% | ― | ― | -63.70% | |
56 Neutral | $2.02B | -9.31 | -59.36% | ― | -86.20% | -476.63% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | $1.94B | -14.08 | -56.19% | ― | -32.27% | -21.09% | |
51 Neutral | $1.67B | -3.54 | -57.79% | ― | 12.58% | 28.42% | |
48 Neutral | $1.91B | -12.57 | -9.96% | ― | -20.44% | -349.84% | |
48 Neutral | $1.07B | -4.96 | -50.12% | ― | -30.42% | -23.31% |
* General Sector Average
BCAX
Bicara Therapeutics Inc.
24.28
12.81
111.68%
SRPT
Sarepta Therapeutics
18.10
-2.89
-13.77%
WVE
Wave Life Sciences
5.41
-4.33
-44.46%
NTLA
Intellia Therapeutics
11.91
1.18
11.00%
STOK
Stoke Therapeutics
31.27
12.76
68.94%
TSHA
Taysha Gene Therapies
5.95
3.02
103.07%
Bicara Therapeutics Inc. Corporate Events
Business Operations and StrategyExecutive/Board Changes
Bicara Therapeutics reshapes board for commercialization push
Positive
Jul 28, 2026
On July 28, 2026, Bicara Therapeutics announced the appointments of industry veterans Jeremy Bender and Christy Oliger to its board of directors, adding deep strategic, commercial and operational expertise as the company transitions from a clinica...
Executive/Board ChangesShareholder Meetings
Bicara Therapeutics Holds 2026 Annual Stockholder Meeting
Neutral
Jun 10, 2026
On June 9, 2026, Bicara Therapeutics Inc. held its 2026 annual meeting of stockholders, where shareholders representing about 85% of the company’s outstanding common stock were present or represented. Stockholders elected Christopher Bowden,...
Business Operations and Strategy
Bicara Highlights Durable Three-Year Data for Ficerafusp Alfa
Positive
May 21, 2026
On May 21, 2026, Bicara Therapeutics reported three-year follow-up data from a Phase 1/1b study of ficerafusp alfa plus pembrolizumab in first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma, showing deep, durable resp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.